Christian Friedrich

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Structural Basis

Pluripotent Stem Cells

Top Venues

British journal of clinical pharmacology

Clinical pharmacokinetics

European journal of drug metabolism and pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Christian Friedrich, Dave Singh, Klaus Francke, Stefan Klein, Terence Hetzel, Oliver Zolk, Isabella Gashaw, Christian Scheerans, Alyn Morice
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men. British journal of clinical pharmacology 90 (8) (2024)
Christian Friedrich, Dave Singh, Klaus Francke, Stefan Klein, Terence Hetzel, Oliver Zolk, Isabella Gashaw, Christian Scheerans, Alyn Morice
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men. British journal of clinical pharmacology (2024)
Christian Friedrich, Klaus Francke, Isabella Gashaw, Christian Scheerans, Stefan Klein, Lueder Fels, Jaclyn Ann Smith, Thomas Hummel, Alyn Hugh Morice
Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study. Clinical pharmacokinetics 61 (8) (2022)
Klaus Francke, Niladri Chattopadhyay, Stefan Klein, Antje Rottmann, Dennis Krickau, Jeroen van de Wetering, Christian Friedrich
Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant. European journal of drug metabolism and pharmacokinetics (2022)
Stefan Klein, Isabella Gashaw, Sybille Baumann, Xinying Chang, Thomas Hummel, Uwe Thuß, Christian Friedrich
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. British journal of clinical pharmacology 88 (10) (2022)